Teva Pharma (TEVA) volatility increases on Mylan (MYL) granted FDA approval of Copaxone

Teva Pharma (NYSE: TEVA) October weekly call option implied volatility is at 70 from 40, October is at 56 from 41, November is at 57; compared to its 52-week range of 24 to 61 on Mylan (Nasdaq; MYL) was granted FDA approval of the first generic for Copaxone.

You May Also Be Interested In

• SpaceX Shares Indicated To Open At $155
• EchoStar Corp. (SATS) call put ratio 3.4 calls to 1 put as share price down 6.4%
• Woodside Energy (WDS) call put ratio 100 calls to 1 put with a focus on July 22.50 calls as share price up 5.8%